Welcome to our dedicated page for Guardian Pharmacy Services SEC filings (Ticker: GRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardian Pharmacy Services, Inc. filings document the reporting obligations of a NYSE-listed long-term care pharmacy services company with Class A common stock. Recent Form 8-K filings furnish operating results, financial guidance, investor presentation materials, and exhibits tied to the company’s pharmacy services business.
Proxy and current-report filings also cover board elections, advisory compensation votes, stockholder voting results, material stock purchase agreements, lock-up arrangements, and conversion-related disclosures involving Class A and Class B common stock. These records describe governance, ownership, capital-structure mechanics, registered securities, and matters linked to the company’s September 2024 corporate reorganization.
Guardian Pharmacy Services, Inc. completed a non-dilutive “synthetic secondary” share offering and shifted its NYSE governance status. The company sold 1,020,000 new Class A shares at a public price of $31.00 per share (less a $1.3175 underwriting discount) as part of a 6,900,000-share underwritten offering, alongside 5,880,000 shares sold by existing holders.
Guardian used all proceeds from its 1,020,000 newly issued shares to repurchase and cancel 1,020,000 outstanding Class A shares from certain holders under stock purchase agreements, so total shares outstanding did not change. Those agreements allow repurchases of up to 1,833,344 shares in private transactions using proceeds from future offerings.
Because the selling stockholders no longer hold a majority of voting power, Guardian ceased to qualify as a NYSE “controlled company” and will comply with full NYSE governance requirements. Effective March 20, 2026, the board formed a Nominating and Governance Committee composed entirely of independent directors.
Guardian Pharmacy Services, Inc. is registering 6,000,000 shares of Class A common stock, consisting of 1,020,000 newly issued shares and 4,980,000 shares offered by the Guardian Founders in a mixed primary and resale offering.
The Company will receive net proceeds of approximately $30.3 million from the 1,020,000 primary shares, which it intends to use to purchase 1,020,000 outstanding Class A shares in a "Synthetic Secondary" at the public offering price less the underwriting discount; after that repurchase the Company does not expect to have remaining net proceeds. The selling stockholders will receive proceeds from their 4,980,000-share resale and the Company will not receive proceeds from those shares. The Guardian Founders’ sales will cause the Company to cease qualifying as a NYSE "controlled company."
Guardian Pharmacy Services, Inc. is registering 5,000,000 shares of Class A common stock in a shelf prospectus supplement dated March 18, 2026. The company is offering 1,020,000 shares and the Guardian Founders are offering 3,980,000 shares.
The company will receive estimated net proceeds of approximately $34.8 million from its 1,020,000-share sale, which it intends to use to purchase 1,020,000 outstanding Class A shares in a “Synthetic Secondary” at the public offering price less underwriting discounts, leaving no remaining net proceeds. The selling stockholders’ sales will not provide proceeds to the company. Guardian’s Class A common stock last traded at $34.09 on the NYSE on March 17, 2026.
Guardian Pharmacy Services, Inc. describes its long-term care pharmacy business in this annual report. The company runs 61 pharmacies, including 54 full-service sites, serving about 205,000 residents in roughly 8,400 facilities across 38 states, with a particular focus on assisted living and behavioral health facilities.
More than two-thirds of revenue comes from these target settings, and about 71% of 2025 revenue was paid through Medicare Part D. Guardian highlights its high-touch service model, extensive automation, proprietary data platforms (Guardian Compass and GuardianShield), and a reported 89% resident adoption rate in assisted living communities it serves.
Guardian Pharmacy Services reported strong 2025 results and raised its 2026 profit outlook. Revenue for 2025 grew to $1.45 billion, with net income attributable to the company improving to $48.96 million from a prior-year loss, and Adjusted EBITDA rising to $115.15 million.
For 2026, Guardian kept its revenue outlook at $1.40–$1.42 billion but increased Adjusted EBITDA guidance to $120–$124 million, reflecting an estimated run-rate of about $110 million exiting 2025. The company ended the year with $65.6 million in cash and no long-term debt outstanding on its $75 million credit facility.
Guardian highlighted operational gains, including the acquisition of North Ridge Pharmacy in Montana, vaccine volume growth with more than 120,000 residents vaccinated in 2025, and an annualized return on equity of about 27%. Management emphasized confidence in the long-term care pharmacy model despite new IRA drug pricing changes.
Forbes Kendall reported acquisition or exercise transactions in this Form 4 filing.
Guardian Pharmacy Services insider Kendall Forbes received an equity award. Forbes was granted 8,952 restricted stock units of Class A common stock at no cash cost, which will vest in full on March 1, 2029. After this grant, Forbes directly holds 799,928 shares or units of Class A common stock.
Morris David K reported acquisition or exercise transactions in this Form 4 filing.
Guardian Pharmacy Services, Inc. director and officer Morris David K reported an equity award of 8,952 shares of Class A common stock on March 1, 2026. The award is in the form of restricted stock units granted at $0.00 per share, bringing his directly held Class A shares to 442,327.
The footnote explains these are restricted stock units that settle one-for-one into Class A common stock when they vest in full on March 1, 2029, highlighting that the award’s value depends on future vesting.
Burke Fred reported acquisition or exercise transactions in a Form 4 filing for GRDN. The filing lists transactions totaling 75,000 shares. Following the reported transactions, holdings were 75,000 shares.
Guardian Pharmacy Services executive Forbes Kendall received a grant of 50,000 stock options on February 11, 2026. The options have an exercise price of $34.59 per share and relate to Class A common stock. They vest and become fully exercisable on February 11, 2029, and expire on February 11, 2036. Following this grant, Kendall beneficially owns 50,000 derivative securities directly.
Morris David K reported acquisition or exercise transactions in a Form 4 filing for GRDN. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.